UPDATE: Sarepta Therapeutics (SRPT) Defended at RBC Capital

Sarepta Therapeutics (NASDAQ: SRPT) is being defended at RBC Capital with the analyst saying the weakness is unfounded and sees a buying opportunity.

Analyst Brian Abrahams comments "We believe there has been some confusion, coming out of an investor presentation this morning, on SPRT's limb girdle muscular dystrophy (LGMD) data and on the regulatory/manufacturing path for microdystrophin gene therapy - leading to stock downside (~9%). Following our discussion/clarifications with the company, we believe timelines and prospects for both remain intact and we remain bullish on both programs; as such, would use any weakness today as a buying opportunity."

You May Also Be Interested In

• Williams-Sonoma (WSM) PT Raised to $260 at RBC Capital
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating